Extracorporeal Membrane Oxygenation Cannula Market (By Type: Veno-arterial, Arterio-venous; By Patient Type: Adult, Pediatric; By Application; By End-use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global extracorporeal membrane oxygenation cannula market size was estimated at around USD 32.18 million in 2023 and it is projected to hit around USD 50.6 million by 2033, growing at a CAGR of 4.63% from 2024 to 2033.

Key Pointers

• North America led the market with the largest market share of 40% in 2023.
• By Type, the veno-arterial cannulae segment captured the maximum market share of 45% in 2023 and is projected to exhibit the fastest CAGR of 5.03% from 2024 to 2033.
• By Patient Type, the adult segment generated the maximum market share in 2023 and is expected to undergo significant growth throughout the forecast period.
• By Application, the respiratory segment held the largest revenue share in 2023.
• By End-use, the hospitals end-use segment held the dominant position in the market in 2023.

Extracorporeal Membrane Oxygenation Cannula Market Overview

The extracorporeal membrane oxygenation (ECMO) cannula market plays a vital role in the field of critical care medicine, offering a lifeline to patients with severe respiratory or cardiac failure. ECMO cannulas are essential components of ECMO systems, facilitating the exchange of oxygen and carbon dioxide in patients whose lungs or heart are unable to function adequately. This overview aims to provide insights into the current landscape of the ECMO cannula market, including market size, key players, growth drivers, challenges, and future prospects.

Extracorporeal Membrane Oxygenation Cannula Market Growth Factors

The growth of the extracorporeal membrane oxygenation (ECMO) cannula market is driven by an increasing incidence of respiratory and cardiac diseases worldwide contributes significantly to the rising demand for ECMO therapy, thus driving the demand for ECMO cannulas. Secondly, advancements in technology, particularly in ECMO systems and cannula design, enhance the efficiency and effectiveness of ECMO therapy, further stimulating market growth. Additionally, heightened awareness among healthcare professionals regarding the benefits of ECMO therapy fosters its adoption, fueling the demand for ECMO cannulas. Moreover, the expansion of healthcare infrastructure in developing economies, coupled with rising healthcare expenditure and insurance coverage for critical care interventions, augments market growth.

Extracorporeal Membrane Oxygenation Cannula Market Trends:

• Miniaturization: The development of smaller and more flexible cannulas allows for minimally invasive ECMO procedures, reducing patient discomfort and complications.
• Integration of Monitoring Capabilities: Integration of monitoring sensors into ECMO cannulas enables real-time monitoring of patient parameters, enhancing treatment precision and patient safety.
• Personalized Cannula Design: Customized ECMO cannulas tailored to patient anatomy and specific clinical requirements are gaining traction, improving treatment outcomes and reducing complications.
• Increasing Adoption of Veno-Arterial ECMO: The growing utilization of veno-arterial ECMO for cardiogenic shock and cardiac arrest management is driving demand for arterial cannulas capable of providing adequate circulatory support.
• Emphasis on Biocompatibility: Manufacturers are focusing on developing biocompatible cannula materials to reduce the risk of thrombosis, inflammation, and infection, thereby improving patient outcomes.
• Expansion in Emerging Markets: Rising awareness of ECMO therapy in emerging economies, coupled with improving healthcare infrastructure and increasing healthcare expenditure, is driving market growth in these regions.

Type Insights

The veno-arterial cannulae segment commanded the market with a share of 45% in 2023 and is projected to exhibit the fastest CAGR of 5.03% from 2024 to 2033, driven by the widespread utilization of Veno-Arterial (VA) ECMO systems and circuits for circulatory and respiratory functions. In ECMO, a return cannula is inserted into a carotid artery, femoral artery, or ascending aorta, while a drainage cannula is placed into an internal jugular or femoral vein. The veno-arterial ECMO circuit is applied in cardiac arrest cases, aiding in algorithmic life support strategies to restore blood circulation and support heart and lung functions.

These promising outcomes for VA-ECMO are expected to drive demand for VA-ECMO cannulae, thus fueling segment growth. The Veno-Venous (VV) cannulae segment is forecasted to experience significant growth in the forthcoming years. This type of cannulation is widely employed in respiratory conditions, including reversible respiratory failure such as ARDS, where blood is drained from a major vein and returned to another major vein. Market players are introducing novel ECMO systems supporting VV cannulation to meet this demand. For instance, in August 2021, Getinge, a leading market player, launched the Rotaflow II extracorporeal life support system tailored for VV ECMO. Such initiatives from key market players are expected to propel segment growth in the foreseeable future

Patient Type Insights

The adult segment claimed the largest market share in 2023 and is expected to undergo significant growth throughout the forecast period, primarily due to the high number of patients afflicted with respiratory conditions such as ARDS. An article published by Yale Medicine in February 2023 revealed that approximately 190,000 individuals in the U.S. are diagnosed with ARDS annually. Furthermore, a study conducted by Egton Medical Information Systems Limited in June 2023 reported that 12.5% of the study population exhibited symptoms of ARDS. This study, conducted in a UK adult University Hospital ICU, analyzed approximately 344 patients. Additionally, the risk of ARDS tends to increase with age, further contributing to the projected growth of this segment as the number of ARDS cases rises.

The pediatric segment is poised to witness lucrative growth over the forecast period, driven by the heightened focus of market participants such as LivaNova PLC, Andocor, Medtronic, and Changzhou KangXin Medical Instruments Co., Ltd., on providing cannulae and ECMO systems tailored for pediatric patients. These companies offer a diverse range of cannula types, including straight tip, curved tip, and flexible options, to address cardiac and respiratory issues in pediatric patients. Consequently, the availability of a broad spectrum of products specifically designed for pediatric patients from major industry players like Medtronic and LivaNova PLC is expected to propel growth within this segment.

Application Insights

The respiratory segment dominated the market in 2023 and is poised for significant growth in the upcoming years, primarily fueled by the widespread utilization of ECMO in various respiratory conditions such as respiratory distress syndrome, respiratory failure, pneumonia, and pulmonary hypertension. Furthermore, the escalating prevalence of these conditions is expected to drive growth within the segment. An article published by the American Lung Association in June 2023 highlighted that approximately 500-1,000 new cases of Pulmonary Arterial Hypertension (PAH) are diagnosed annually in the U.S. Additionally, a study published by PLOS in January 2022 revealed that ARDS affects approximately 10% of patients admitted to ICUs globally, with the U.S. recording as many as 190,600 cases per year.

Consequently, the substantial patient population afflicted with respiratory conditions amenable to ECMO treatment is anticipated to propel growth within the segment. The Extracorporeal Cardiopulmonary Resuscitation (ECPR) segment is projected to exhibit the fastest CAGR from 2024 to 2033, driven by the increasing adoption of ECPR for treating patients with cardiac arrest who are unresponsive to conventional cardiopulmonary resuscitation methods. Moreover, ECPR incorporates VA ECMO cannulation in cases of refractory cardiac arrest.

End-use Insights

The hospitals end-use segment held the dominant position in the market in 2023, as hospitals remain the preferred healthcare settings for treatments and surgeries, offering a wide range of services under one roof. Many hospitals are increasingly prioritizing ECMO programs, with respiratory and cardiac surgeries commonly performed in major hospital facilities. For example, Sahyadri Hospital stands out as a major cardiac surgery hospital in India, conducting approximately 75 cardiac surgeries and 80 angioplasties each month. Moreover, the growing number of hospitals such as Northwell Health and Barnes-Jewish Hospital offering treatments and surgeries for respiratory and cardiac patients is expected to further drive growth within this segment.

The ambulatory surgical centers (ASCs) segment is projected to witness the fastest CAGR from 2024 to 2033. Technological advancements and the increasing prevalence of ASCs are key factors driving the demand for treatments at these centers. Additionally, ASCs offer a cost-effective and high-quality alternative to hospital care for surgical treatments. Furthermore, industry players are increasingly focusing on providing cardiovascular procedures through ASCs due to their rising popularity. For instance, in June 2022, Atlas Healthcare Partners, in collaboration with MedAxiom, established a cardiovascular-focused ASC company, aiming to perform a growing number of cardiac surgeries in ASCs, thus propelling segment growth.

Regional Insights

The North America accounted for the largest revenue share in 2023, at 40%, primarily attributed to the region's well-established healthcare sector, commitment to innovation, advanced infrastructure, robust emphasis on research and development (R&D), and the high prevalence of chronic conditions such as cardiovascular diseases (CVDs). According to the CDC, approximately six out of ten American adults suffer from at least one chronic condition requiring specialized care. Additionally, favorable government regulations and reimbursement policies further bolster the region's dominance. Regulatory bodies like the FDA uphold stringent quality standards, ensuring the safety and efficacy of various healthcare products, including ECMO cannulas, which instills confidence among healthcare professionals and patients alike.

The APAC ECMO cannula market presents a significant growth opportunity, driven by the increasing adoption of ECMO therapy and government support. However, the market landscape in the region is fragmented. While established players like Medtronic maintain a strong foothold, emerging regional competitors from countries like China and India are gaining prominence. Strategic partnerships with local players and conducting clinical trials within the region are deemed crucial for driving market growth.

Extracorporeal Membrane Oxygenation Cannula Market Key Companies

• Medtronic
• LivaNova PLC
• Edwards Lifesciences Corporation
• Getinge
• Andocor
• Changzhou KangXin Medical Instruments Co., Ltd
• Free Life Medical GmbH
• Fresenius Medical Care AG
• Abbott

Extracorporeal Membrane Oxygenation Cannula Market Segmentations:

By Type

• Veno-Arterial
• Veno-Venous
• Arterio-Venous

By Patient Type

• Neonates
• Pediatric
• Adult

By Application

• Respiratory
• Cardiac
• ECPR

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)